The VSV-EBOV Ebola vaccine developed by the Public Health Agency of Canada has passed phase I clinical trials, according to results published in The New England Journal of Medicine.
The phase I trials, conducted at the Walter Reed Army Institute of Research and the National Institute of Allergy and Infectious Diseases in the United States and published on 1 April, show that the vaccine is safe to use in humans. It will now proceed to phase 3 trials to determine if it works.
Health minister Rona Ambrose said in a press release: “Canada is pleased that clinical studies have demonstrated the safety of Canada’s VSV-EBOV Ebola vaccine. We are proud of the work done by Public Health Agency of Canada scientists that led to the development of the vaccine and hope that it can be used as a global resource to help save lives and end the outbreak in West Africa.”
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.